Groowe Groowe / Newsroom / GILD
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

GILD News

Gilead Sciences Inc

Growth Factors Market to Reach US$ 3.7 Bn by 2033, Expands Amid Rising Regenerative Medicine and Biopharmaceutical Innovation - Persistence Market Research

prnewswire.com
TMO MRK BIO BIIB AMGN GILD REGN CRSP NTLA BMY ABBV AZN NVS PFE JNJ MRNA BNTX COR STEM ALGN EXAS MDLZ BHC CVS UNH CI CNC ELAN ZTS ISRG QRVO SWKS AVGO QCOM INTC MSFT GOOG AMZN IBM ORCL CRM ADBE NFLX DIS MCD SBUX KO PEP PG JPM BAC WFC C GS MS AXP V MA HD LOW COST TGT WMT BBY CMCSA VZ T XOM CVX SIRI UBER LYFT NVDA AMD MU AMAT LRCX ASML ADI TXN QGEN ILMN VRTX EDIT BEAM SRPT ACAD ALKS MDT SYK DHR GOOGL

U.S. Orphan Drug Market Report 2026: A $200 Billion Opportunity by 2031 - Indication, Company, Trial Phase, Marketed Status of 1400 Drugs, Drug Sales of 150 Drugs, Pricing and Dosage of 400 Drugs

globenewswire.com
BMY GILD JNJ SNY TAK AMGN AZN LLY MRK PFE REGN VRTX ABBV ALNY AMTX BIIB BMRN CRSP EXAS INCY IONS JAZZ NTLA PTC RGEN XOM

Metabolon's Metabolomics Platform Enables Largest Metabolomic Analysis to Date in CAR T-Cell Therapy, Revealing New Insights into Severe Neurotoxicity USA - English India - English

prnewswire.com
GILD

Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options

businesswire.com
GILD

Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options

businesswire.com
GILD

IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

globenewswire.com
FATE INDP AMGN NKTR IBIO TAK SNY INMB CLMT VERX GTBP BHVN CHRS GSK BMY MRK ABBV AZN GILD LLY KYMR REGN SPRY

CAR T-Cell Therapy Market worth $13.78 billion by 2031 | MarketsandMarkets™

prnewswire.com
BMY GILD JNJ CRSP ALLO CART

World-First EXO 001 Exosome Platform Enables In Vivo Multi-Target CAR-T for Solid Tumors

prnewswire.com
GILD AZN BMY ABBV

BCL-2 Inhibitors Market Poised for Robust Growth During the Forecast Period (2025-2034) as Oncology Pipelines Expand | DelveInsight

prnewswire.com
ABBV AMGN AZN BMY GILD JNJ LLY MRK NVS PFE SNY TMO

Terray’s New EMMI Predict Model Sets an Industry Performance Standard – Delivering Best-In-Class Accuracy, 26x Faster

businesswire.com
GILD